Germ cell tumour of testis

Area of Science:

• Oncology
• Medical Chemotherapy
• Urologic Oncology

Background:

• Germ cell tumors are the most common malignancy in young men (15-35 years), with survival rates dramatically improving since the 1970s.
• Effective management relies on advanced diagnostics, biological markers, and platinum-based chemotherapy.
• Non-seminomatous germ cell tumors (NSGCT) are typically treated with 3-drug regimens, but high cost (Bleomycin) and poor compliance are significant issues.

Purpose of the Study:

• To evaluate the efficacy of a 2-drug chemotherapy regimen (Platinum and Etoposide - PE) for testicular germ cell tumors.
• To assess the feasibility and outcomes of the PE regimen as an alternative to more expensive 3-drug protocols.

Main Methods:

• A retrospective study of 40 testicular tumor cases treated between January 1992 and December 1994.
• Patients received either a PEB (Platinum, Etoposide, Bleomycin) regimen (16 cases) or a PE regimen (24 cases).
• The PE regimen involved 6 cycles of Platinum (20 mg/m2 D1-D5) and Etoposide (VP-16, 100 mg/m2 IV D1-D5) every three weeks.

Main Results:

• Twenty patients completed the PE regimen; 17 (85%) showed complete disease regression by June 1996.
• Two patients experienced progressive disease and required alternative treatment.
• The 18-month disease-free survival rate for the PE regimen group was 85%.

Conclusions:

• The 2-drug Platinum and Etoposide (PE) regimen is an effective treatment for testicular germ cell tumors, achieving high complete regression and disease-free survival rates.
• The PE regimen offers a potentially more cost-effective and compliant alternative to standard 3-drug chemotherapy for NSGCT.
• Further research is warranted to confirm the long-term efficacy and broader applicability of the PE regimen in managing germ cell malignancies.